Inhibitor Therapeutics, Inc.
INTI · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.38 | -1.01 | 0.06 | -0.02 |
| FCF Yield | -8.88% | -8.10% | -14.91% | -7.45% |
| EV / EBITDA | -7.65 | -5.11 | -6.49 | -3.34 |
| Quality | ||||
| ROIC | -24.10% | -18.22% | -15.13% | -29.77% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.07 | 0.88 | 2.03 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -30.35% | 54.55% | -66.57% | -7.08% |
| Safety | ||||
| Net Debt / EBITDA | 3.92 | 5.26 | 6.28 | 3.94 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |